Type your tag names separated by a space and hit enter
Cyclomydril Ophthalmic Solution
There's more to see -- the rest of this topic is available only to subscribers.
Vallerand, April Hazard., et al. "Cyclomydril Ophthalmic Solution." Davis's Drug Guide, 18th ed., F.A. Davis Company, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/50212/all/Cyclomydril_Ophthalmic_Solution.
Vallerand AHA, Sanoski CAC, Quiring CC. Cyclomydril Ophthalmic Solution. Davis's Drug Guide. F.A. Davis Company; 2023. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/50212/all/Cyclomydril_Ophthalmic_Solution. Accessed September 22, 2023.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Cyclomydril Ophthalmic Solution. In Davis's Drug Guide (18th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/50212/all/Cyclomydril_Ophthalmic_Solution
Vallerand AHA, Sanoski CAC, Quiring CC. Cyclomydril Ophthalmic Solution [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2023. [cited 2023 September 22]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/50212/all/Cyclomydril_Ophthalmic_Solution.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Cyclomydril Ophthalmic Solution
ID - 50212
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/50212/all/Cyclomydril_Ophthalmic_Solution
PB - F.A. Davis Company
ET - 18
DB - Pediatrics Central
DP - Unbound Medicine
Try the app for free!
1. Download the Pediatrics Central app by Unbound Medicine
2. Select Try/Buy and follow instructions to begin your free 30-day trial
You can cancel anytime within the 30-day trial, or continue using Pediatrics Central to begin a 1-year subscription ($39.95)
Your free 1 year of online access expired .
Want to regain access to Pediatrics Central?
Log in to Pediatrics Central
If you need further assistance, please contact Support.